Is the intranasal live‑attenuated influenza vaccine as effective as the intramuscular inactivated influenza vaccine?

Is the intranasal (LAIV) flu vaccine as effective as the intramuscular (IIV) vaccine?

Yes—among eligible, healthy persons aged 2–49 years, intranasal LAIV is an acceptable option with no overall preference over inactivated IM vaccines; choose either based on age/health status and availability. 1

Bottom-line recommendation (morbidity, mortality, QOL prioritized)

• Use either LAIV (intranasal) or IIV (intramuscular) for healthy, nonpregnant persons 2–49 years; no preference by ACIP 2024–25. This supports broad vaccination to reduce hospitalizations and complications (drivers of morbidity, mortality, and QOL). 1
• Prefer IIV (not LAIV) for:
  • Age <2 or ≥50 years, pregnancy, chronic conditions (e.g., asthma, immunocompromise), aspirin therapy in ≤17 years, or close contact with profoundly immunosuppressed in protective environments. These restrictions avoid harm that would worsen outcomes. 2, 3, 1, 4

How the evidence guides choice

• Guideline (most recent/highest quality):
  • 2024–25 ACIP: LAIV is indicated for healthy, nonpregnant 2–49 years; within indicated groups, no preference for LAIV vs IIV. 1
• Key nuance from prior guidance and label:
  • Past LAIV underperformance vs A(H1N1)pdm09 in 2013–16 led to temporary non‑use; updated strains since 2018 restored ACIP as an option. This affects season-to-season expectations but current guidance allows use. 5
  • FDA label: LAIV not approved <24 months (↑ wheeze/hospitalization), avoid with aspirin therapy ≤17 years, and be aware of interference with antivirals ±2 weeks. These protect against adverse outcomes. 4
• Research (to augment, not override guidelines):
  • Children: RCT showed LAIV superior to IIV in preventing culture‑confirmed influenza in 6–59 months (but note LAIV contraindicated <24 months); supports strong effectiveness signal in pediatrics where eligible. 6
  • Real‑world meta‑analysis 2003–2023: LAIV and IIV had similar overall effectiveness post‑2017 updates; LAIV comparable for A(H1N1)/A overall and potentially better for B in children—consistent with using either to reduce illness burden. 7

Practical algorithm

1. Check eligibility:
   • Age 2–49, healthy, nonpregnant, no asthma/reactive airways, no immunosuppression, no aspirin therapy (≤17 y), not within ±2 weeks of anti‑influenza antivirals. If any “no,” choose IIV. 2, 3, 1, 4
2. If eligible:
   • Offer either LAIV (intranasal) or IIV (IM); base on patient preference/availability—both acceptable with no preference. 1
3. Special situations/pitfalls:
   • Copious nasal congestion may impair LAIV delivery—use IIV that day. 8
   • Household contacts of severely immunosuppressed in protective settings: prefer IIV to avoid theoretical LAIV transmission risk. 3
   • Avoid LAIV if recent/anticipated oseltamivir, zanamivir, baloxavir exposure within 48h before to 2 weeks after vaccination; consider revaccination if given together. 4

Caveats and pitfalls to avoid

• Do not give LAIV to:
  • <2 y, ≥50 y, pregnant, asthma/chronic pulmonary/cardiac, immunocompromised, aspirin therapy in ≤17 y, history of severe allergy to components. These reduce serious adverse event risks. 2, 3, 1, 4
• Do not coadminister LAIV close to live vaccines without 4‑week spacing if not simultaneous. 9, 8
• Document antiviral timing; reschedule LAIV or choose IIV when antivirals are used. 4

When sources diverge

• Older AAP/ACIP materials noted LAIV sometimes superior in children and IIV possibly better in young adults; current ACIP 2024–25 resolves this by stating no preference within indicated groups—follow current guidance for practice. 8, 1

In sum: for healthy, eligible 2–49-year-olds, intranasal LAIV and intramuscular IIV are both appropriate and similarly effective options to prevent influenza-related complications; use IIV when any LAIV contraindication exists. 1